OMGA News and Press, Omega Therapeutics Inc. From 05/06/24

2024-05-06 07:54:43 ET More on Omega Therapeutics Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy' Seeking Alpha’s Quant Rating on Omega Therapeutics Historical earnings data for Omega Therapeutics Financial information for Omega The...

Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024 Presented new preclinical data demonstrating potential of a MYC-targeting epigenomic controller in NSCLC at AAC...

2024-04-25 17:31:10 ET Gainers: Alphabet  ( GOOGL ) +15% . Alphabet  ( GOOG ) +15% . Exponent ( EXPO ) +13% . Columbia Sportswear ( COLM ) +8% . SPS Commerce ( SPSC ) +6% . Losers: Intel Corporation ( INTC )...

CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will present a poster at the America...

2024-04-17 17:01:03 ET Gainers: Vanda Pharmaceuticals  ( VNDA ) +7% . Sutro Biopharma ( STRO ) +5% . CureVac  ( CVAC ) +5% . CorMedix  ( CRMD ) +4% . Bank OZK ( OZK ) +4% . Losers: Omega Therapeutics ( OM...

2024-04-16 16:47:42 ET More on Omega Therapeutics Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy' Seeking Alpha’s Quant Rating on Omega Therapeutics Historical earnings data for Omega Therapeutics Financial information for Omega The...

MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardless of underlying resistance mechanism Validation of novel translational assay enables detection and quantification of site-specific DNA methylation from liquid biops...

2024-04-03 08:00:08 ET Edward Tenthoff from Piper Sandler issued a price target of $9.00 for OMGA on 2024-04-03 06:48:00. The adjusted price target was set to $9.00. At the time of the announcement, OMGA was trading at $3.01. The overall price target consensus is at $9.0...

2024-03-31 06:22:14 ET Summary Omega Therapeutics is a biotech company focused on developing programmable epigenomic mRNA medicines to control gene manifestation. The company's platform has applications in various diseases, including hepatocellular carcinoma, non-small cell lung c...

2024-03-28 14:56:38 ET More on Omega Therapeutics Omega Therapeutics: The Next Weight Loss Drug Runner Omega Therapeutics: Starting 2024 With A Bang Novo Nordisk signs research deals on cardiometabolic diseases Seeking Alpha’s Quant Rating on Omega The...